Midatech Pharma PLC SEC filing regarding share price movement
May 08 2018 - 1:01AM
RNS Non-Regulatory
TIDMMTPH
Midatech Pharma PLC
08 May 2018
8 May 2018
Midatech Pharma PLC
("Midatech" or the "Company")
SEC filing regarding share price movement
Midatech (AIM: MTPH, Nasdaq: MTP), the international specialty
pharmaceutical company focused on developing and commercialising
products in oncology, notes that, in connection with its disclosure
obligations as a company registered with the U.S. Securities and
Exchange Commission (SEC), on 4 May 2018 the Company filed with the
SEC a Form 6-K reconfirming that it is unaware of the reason for
the recent trading activity in the Company's securities. As
previously disclosed, the Company is reviewing a range of options
to meet its cash flow needs, including non-dilutive financing
and/or other strategic alternatives.
- Ends -
For more information, please contact:
Midatech Pharma PLC
Craig Cook, CEO-designate
Nick Robbins-Cherry, CFO
Tel: +44 (0)1235 888 300
www.midatechpharma.com
Panmure Gordon (UK) Limited (Nominated Adviser and Broker)
Freddy Crossley / Emma Earl / Ryan McCarthy
Tel: +44 (0)20 7886 2500
Consilium Strategic Communications (Financial PR)
Mary Jane Elliott / Ivar Milligan / Nicholas Brown
Tel: +44 (0)20 3709 5700
Email: midatech@consilium-comms.com
Westwicke Partners (US Investor Relations)
Chris Brinzey
Tel: +1 339 970 2843
Email: chris.brinzey@westwicke.com
Notes for Editors
About Midatech Pharma PLC
Midatech is an international specialty pharmaceutical company
focused on the research and development of a pipeline of medicines
for oncology and immunotherapy. Midatech's strategy is to
internally develop oncology products, and to drive growth both
organically and through strategic acquisitions. The Company's
R&D activities are focused on three innovative platform
technologies to deliver drugs at the "right time, right place":
gold nanoparticles ("GNPs") to enable targeted delivery; Q-Sphera
polymer microspheres to enable sustained release ("SR") delivery;
and Nano Inclusion ("NI") to provide local delivery of
therapeutics, initially to the brain. Midatech Pharma US is the
Group's US commercial operation, with four cancer supportive care
products and two further co-promoted products The Group, listed on
AIM: MTPH and Nasdaq: MTP, employs c.100 staff in four countries.
For further company information see: www.midatechpharma.com
Forward-Looking Statements
Certain statements in this press release may constitute
"forward-looking statements" within the meaning of legislation in
the United Kingdom and/or United States. Such forward-looking
statements include, but are not limited to, statements regarding
the ability of Midatech to successfully test, manufacture, produce
or commercialize products for conditions using the nanoparticle and
sustained release drug delivery platforms, and the ability for
products in development to achieve positive clinical results, and
the ability to meet or achieve timelines associated with
pre-clinical studies, clinical trials or regulatory submissions.
Any forward-looking statements are based on currently available
competitive, financial and economic data together with management's
views and assumptions regarding future events and business
performance as of the time the statements are made and are subject
to risks and uncertainties. We wish to caution you that there are
some known and unknown factors that could cause actual results to
differ materially from any future results, performance or
achievements expressed or implied by such forward-looking
statements.
Reference should be made to those documents that Midatech shall
file from time to time or announcements that may be made by
Midatech in accordance with the London Stock Exchange AIM Rules for
Companies ("AIM Rules"), the Disclosure and Transparency Rules
("DTRs") and the rules and regulations promulgated by the US
Securities and Exchange Commission, which contains and identifies
other important factors that could cause actual results to differ
materially from those contained in any projections or
forward-looking statements. These forward-looking statements speak
only as of the date of this announcement. All subsequent written
and oral forward-looking statements by or concerning Midatech are
expressly qualified in their entirety by the cautionary statements
above. Except as may be required under the AIM Rules or the DTRs or
by relevant law in the United Kingdom or the United States,
Midatech does not undertake any obligation to publicly update or
revise any forward-looking statements because of new information,
future events or otherwise arising.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAARMLTMBJMBAP
(END) Dow Jones Newswires
May 08, 2018 02:01 ET (06:01 GMT)
Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From Apr 2024 to May 2024
Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From May 2023 to May 2024